Literature DB >> 156097

Identification of keratan sulfate in liver affected by Morquio syndrome.

R Minami, K Abo, T Kudoh, S Tsugawa, K Oyanagi, T Nakao.   

Abstract

Glycosaminoglycan content, composition and molecular weight were determined in liver obtained from a patient with Morquio syndrome (Mucopolysaccharidosis IV). There was about a four-fold increase in glycosaminoglycan content (as hexosamine) of the affected liver as compared to the control liver. The major glycosaminoglycan accumulated in the liver was keratan sulfate, which was not found in the control liver. Chondroitin sulfates, especially chondroitin 6-sulfate, were also increased. Heparan sulfate isolated from the liver of a patient with Morquio syndrome was structurally different to that from control liver, and the glycosaminoglycans from Morquio syndrome were of a much lower molecular weight than those from control.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 156097     DOI: 10.1016/0009-8981(79)90090-1

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Ocular histopathology and ultrastructure of Morquio syndrome (systemic mucopolysaccharidosis IV A).

Authors:  M Iwamoto; Y Nawa; I H Maumenee; J Young-Ramsaran; R Matalon; W R Green
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Morquio's disease type A: absence of material cross reacting with antibodies against N-acetylgalactosamine-6-sulfate sulfatase.

Authors:  J Glössl; K Lembeck; G Gamse; H Kresse
Journal:  Hum Genet       Date:  1980       Impact factor: 4.132

3.  Prenatal diagnosis of Hurler's syndrome--biochemical studies on the affected fetus.

Authors:  T Ikeno; R Minami; K Wagatsuma; S Fujibayashi; T Nakao; K Abo; S Tsugawa; S Taniguchi; Y Takasago
Journal:  Hum Genet       Date:  1981       Impact factor: 4.132

4.  Impaired degradation of keratan sulphate by Morquio A fibroblasts.

Authors:  J Glössl; H Kresse
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

Review 5.  Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA.

Authors:  Christian J Hendriksz; Maisoon Al-Jawad; Kenneth I Berger; Sara M Hawley; Rebecca Lawrence; Ciarán Mc Ardle; C Gail Summers; Elizabeth Wright; Elizabeth Braunlin
Journal:  J Inherit Metab Dis       Date:  2012-02-23       Impact factor: 4.982

6.  Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.

Authors:  Melita Dvorak-Ewell; Dan Wendt; Chuck Hague; Terri Christianson; Vish Koppaka; Danielle Crippen; Emil Kakkis; Michel Vellard
Journal:  PLoS One       Date:  2010-08-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.